EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis

Michael M Poon iD, Kym I Lorrain, Karin J Stebbins, Geraldine C Edu, Alexander R Broadhead, Ariana J Lorenzana, Jeffrey R Roppe, Jill M Baccei, Christopher S Baccei, Austin C Chen, Ari J Green, Daniel S Lorrain und 1 weitere

Proceedings of the National Academy of Sciences · 2024

DOI: 10.1073/pnas.2407974121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Michael M Poon und 12 weiteren Autor:innen. Beteiligte Einrichtung: Contineum Therapeutics, San Diego, CA 92121. Hauptthemen laut MEDLINE: Multiple Sclerosis, Oligodendroglia, Receptor, Muscarinic M1, Remyelination. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HHS | NIH | National Institute of Mental Health (NIMH), Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF), HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is a chronic and debilitating neurological disease that results in inflammatory demyelination. While endogenous remyelination helps to recover function, this restorative process tends to become less efficient over time. Currently, intense efforts aimed at the mechanisms that promote remyelination are being considered promising therapeutic approaches. The M1 muscarinic acetylcholine receptor (M1R) was previously identified as a negative regulator of oligodendrocyte differentiation and myelination. Here, we validate M1R as a target for remyelination by characterizing expression in human and rodent oligodendroglial cells (including those in human MS tissue) using a highly selective M1R probe. As a breakthrough to conventional methodology, we conjugated a fluorophore to a highly M1R selective peptide (MT7) which targets the M1R in the subnanomolar range. This allows for exceptional detection of M1R protein expression in the human CNS. More importantly, we introduce PIPE-307, a brain-penetrant, small-molecule antagonist with favorable drug-like properties that selectively targets M1R. We evaluate PIPE-307 in a series of in vitro and in vivo studies to characterize potency and selectivity for M1R over M2-5R and confirm the sufficiency of blocking this receptor to promote differentiation and remyelination. Further, PIPE-307 displays significant efficacy in the mouse experimental autoimmune encephalomyelitis model of MS as evaluated by quantifying disability, histology, electron microscopy, and visual evoked potentials. Together, these findings support targeting M1R for remyelination and support further development of PIPE-307 for clinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisOligodendrogliaReceptor, Muscarinic M1RemyelinationAnimalsHumansMiceRatsBrainEncephalomyelitis, Autoimmune, ExperimentalMice, Inbred C57BLMuscarinic AntagonistsMyelin Sheath

Stichwörter der Autor:innen

multiple sclerosismuscarinic receptorsmyelinationoligodendrocyte

Substanzen

Muscarinic AntagonistsReceptor, Muscarinic M1

Autor:innen und Institutionen

  • Contineum Therapeutics, San Diego, CA 92121.
  • Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA 94158.

ORCID-Profile: Michael M Poon, Jonah R Chan

Förderung

  • HHS | NIH | National Institute of Mental Health (NIMH)
  • Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF)
  • HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
  • NINDS NIH HHS
  • NIMH NIH HHS

Zitieren

APA

Poon, M. M., Lorrain, K. I., Stebbins, K. J., Edu, G. C., Broadhead, A. R., Lorenzana, A. J., Roppe, J. R., Baccei, J. M., Baccei, C. S., Chen, A. C., Green, A. J., Lorrain, D. S., & Chan, J. R. (2024). Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2407974121

Vancouver

Poon MM, Lorrain KI, Stebbins KJ, Edu GC, Broadhead AR, Lorenzana AJ, et al. Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2407974121

BibTeX
@article{Poon2024,
  author = {Poon, Michael M and Lorrain, Kym I and Stebbins, Karin J and Edu, Geraldine C and Broadhead, Alexander R and Lorenzana, Ariana J and Roppe, Jeffrey R and Baccei, Jill M and Baccei, Christopher S and Chen, Austin C and Green, Ari J and Lorrain, Daniel S and Chan, Jonah R},
  title = {Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  doi = {10.1073/pnas.2407974121}
}
Kostenlos starten →